Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.
Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Click Here For The Most Popular On Sunny Skyz
Football Player Asks Friend With Down Syndrome To Homecoming
People Are Sharing Their Oddly Romantic Date Stories, And They’ll Make You Smile So Big
This Pit Bull Was Days Away From Being Euthanized. Now, He's A Police Hero
Hospital Staff Go Above And Beyond To Keep Couple’s 62-Year Anniversary Tradition Alive
Strangers Send Man Birthday Wishes At The Exact Minute His Late Mom Used To
Hope And Hard Work: Jail Resident Makes History In Clarke County
Toddler’s 3 A.M. DJ Session Has the Internet Cracking Up
Dad Dresses As Beast To Walk His Daughter to School And It’s Melting Hearts Everywhere
This Turkey Was Heartbroken — Until Her Owner Gave Her The Sweetest Surprise
They Found Out He Couldn’t Afford The Shirt. Their Response Went Viral For All The Right Reasons
The Last Runner To Cross The NYC Marathon Finish Line Got The Biggest Ovation Of All
